x min read


Published on
August 17, 2022
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook

In this article, we look at 4 top OTC stocks that will be part of the next big bull run, including Brookmount Explorations Inc (OTCPK: BMXI), Greene Concepts, Inc (OTCPK: INKW),Rafarma Pharmaceuticals, Inc (OTCPK: RAFA), and Regen BioPharma Inc (OTCPK: RGBP). Top OTC stocks #1 BMIX Top OTC stocks #2 INKW Top OTC stocks #3 RAFA Top OTC stocks #4 RGBP


It has been a great month so far for Brookmount Explorations Inc, which has tripled in price during the last five trading sessions, surging from about $0.05 on August 9 to the current level at $0.16. On Monday, the share price of the Pink Current stock broke above $0.18 for the first time since March, reversing a multi-month downtrend that started in mid-March near $0.25.BMXI is an operator producing gold properties in the Republic of Indonesia. The company currently operates two gold-producing properties in volcanic-hosted sediment within the tropical rainforest region of Sulawesi Province in northeast Indonesia. It is acquiring additional high-grade properties in the area, originally surveyed and developed by Newmont Mining of the US.The Nevada-based company is looking to acquire, explore and develop mineral properties. It recently acquired a 5000-hectare gold property in the Tintina gold belt in the Yukon area of Canada.The finalization of the latest acquisition was announced on August 15, which pushed the share price even higher. BMXI purchased the McArthur Creek property announced in July. The property is located on the Alaska (US) side of the Tintina Gold Belt and is contiguous with the company’s Moosehorn property in the Yukon (Canada), containing a 250 HA reserve of high-quality ore.The newly acquired property features direct access from Moosehorn to the Trans Alaska Highway, greatly improving access for heavy equipment, such as crushers and ball mills, inward to the site, and ore and ore concentrate outward to refineries situated on the Yukon side of the border.BMXI CEO Nils Ollquist commented:

“I am delighted to be able to confirm the finalisation of our first investment in the USA. The McArthur property is a perfect complement to our Moosehorn reserve, with identical geological structure, comprising both placer and hard rock deposits, and a partly contiguous border which facilitates highway access to enable efficient movement of heavy equipment to both properties, and semi processed product to refineries.”

The $17 million company will benefit from this deal as it will contribute to its financials, which are already improving. In the first quarter, BMXI reported a net profit of almost $2 million, up 46% from $1.3 million for the comparable period in 2021. Revenue for the quarter was $4.6 million, up by 43% over the same period in 2021.BMXI is also applying to uplist to Nasdaq or NYSE, so this is only the start of something much bigger. If you consider BMXI’s gold reserves, the real price for BMXI should be well above $5, so watch this stock closely!https://twitter.com/stock_hacker/status/1558104481467977728


Greene Concepts, Inc shares a similar story, although the company operates in the beverages industry. INKW is a $14 million company that saw its share price more than tripling since the beginning of August, surging from about $0.005 at the start of the month to the current level of $0.0176. On Monday, it hit $0.0188, which is the highest level since October.INKW, through its subsidiary, Mammoth Ventures Inc., operates as a bottling and beverage company. The bottling facility has as its water sources a combination of seven spring and artesian wells that are fed from a natural aquifer that is located deep below the Pisgah National Forest. Mammoth Ventures produces a variety of beverage product lines, including but not limited to spring and artesian water, CBD-infused beverages, pH-balanced water and beverage offerings, and enhanced athletic drinks in addition to other product offerings.At the beginning of the year, we mentioned INKW as one of the OTC stocks to watch this year, and the company doesn’t disappoint.The latest price increase came after the company announced the official launch of its Happy Mellow immune support CBD beverage, which is available on the Happy Mellow website. The Pink Current company previously announced the completion of its first Happy Mellow production.All three Happy Mellow flavors are now available for purchase, including “Be Well” Blood Orange Acai (with Vitamin C), “Be Energized” Lemon Lime (with Caffeine and Vitamin D-3), and “Be Calm” Plum Punch (with Vitamin B12).Six Packs are sold for $29.99. The CBD beverages incorporate a proprietary patent-pending water-soluble technology that greatly enhances product effectiveness.At the beginning of the month, the company said it had several announcements to be released soon.https://twitter.com/GreeneConcepts/status/1555635336159678464On Tuesday, INKW said it implemented some improvements at its Marion, NC, beverage & bottling plant. Improvements include the resurfacing of its roadway, driveway, and parking lot, repainting of the building’s interior and exterior, improving the LED lighting, power washing and painting of the entire plant, and purchasing a double forklift to quicken the load capability of its products into tractor trailers for nationwide distribution. This augments the previously announced bottling plant enhancements in the company’s March 15, 2021 release.Ken Porter, Greene Concepts bottling plant manager, stated:

“As sales continue to expand nationally and locally, the company experiences increased trailer traffic to its bottling plant. Resurfacing of all surrounding roadways leading to and around the plant, along with our parking lot, prepares our production facility to better receive trailers from larger national retail outlets.”

INKW is ready for another big announcement this week, which could help the share price break above the $0.02 mark. INKW is a great stock as it generates sales that are expanding, especially with the launch of a new product line.[embed]https://www.youtube.com/watch?v=Vqdl4vAICpw[/embed]


Rafarma Pharmaceuticals, Inc is a Pink Current pharmaceutical company that is bouncing back to April-May levels, trading above $0.7. The $100+ million company saw its share price gaining over 50% since the beginning of the month to trade at $0.61, after almost touching the $0.7 mark on Monday.RAFA produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company collaborates with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease.On Monday, RAFA released solid financials, with six-month revenue coming in at $46.1 million, net income exceeding $4.5 million, and total assets at $132 million. The company’s EPS came in at 5.2 cents.https://twitter.com/RafarmaPharma/status/1559261378304786433The company achieved visible progress with its research and production pharma cluster in Uzbekistan, which was first announced in April of this year. The Tashkent Pharma Park will strengthen the company’s position in Central Asia.https://twitter.com/RafarmaPharma/status/1557769468620718080RAFA has strong fundamentals as the company increases revenues from drug sales and is building a big pharma cluster in Uzbekistan. RAFA is eyeing the $1 mark soon.


The last time when we discussed Regen BioPharma Inc back in May, it was trading at $0.004, eventually touching the lowest level this year a few days later. Since then, the share price has managed to gradually recover and is now trading above the penny mark after gaining over 100% during the last month alone.Our readers and subscribers are familiar with RGBP, as we believe this Pink Current stock can provide great value in the long term, as the company can monetize its multiple patents.RGBP is focused on the immunology and immunotherapy space. The company is working on molecule therapies for treating cancer and autoimmune disorders. On top of that, Regen is working on translational medicine platforms for the commercialization of stem cell therapies. RGBP produces stem-based medicines for diabetes, heart-related illness, circulatory issues, and Chronic Obstructive Pulmonary Disease. The stem cell industry is expected to exceed $15 billion by 2027.RGBP has an extensive intellectual property portfolio, and it’s about to add another patent on its list. At the end of July, the $50+ million company said it was filing with the United States Patent and Trademark Office (USPOTI) a provisional patent application covering utilization of dendritic cell technologies to augment efficacy of its patented survivin mRNA cancer immunotherapeutic vaccine.Last year, RGBP was granted US patent # 11,090,332 on composition of matter of survivin modified-mRNA useful for teaching the immune system to kill cancer. In the current patent, specific types of dendritic cells, means of generating specialized dendritic cells, and the planned formulation that will enter clinical trials have been granted patent protection.RGBP CEO Dr. David Koos commented:

“We are proud of our collaborators and colleagues who have worked on our first issued survivin patent, which was filed in 2015, before the world realized the potency of modified-mRNA technology that was first successfully commercialized with the COVID-19 vaccines by Moderna and Pfizer. The currently filed application discloses means of significantly increasing efficacy by combining modified-mRNA with unique cellular immunotherapy as well as adjuvant approaches. We chose this strategy to maximally protect our intellectual property around this potentially very valuable mRNA cancer immunotherapy vaccine.”

Immunotherapy of cancer represents a very large market which is currently being led by the class of drugs called ‘checkpoint inhibitors’ and ‘CAR-T’ cells. To date, there is no mRNA immunotherapy available for treating cancer. This patent application protects the use of our patented survivin mRNA both as a stand-alone vaccine and as an immunotherapy.Meanwhile, RGBP filed another provisional US patent application cover its novel approach for enabling chimeric antigen receptor (CAR)-T cell-based therapies to kill solid tumors through prevention of a process called “T cell exhaustion.”CAR-T cells are very effective at treating certain lymphomas and leukemias with an overall cure rate of over 50%. However, solid tumors remain resistant to CAR-T therapies for many reasons. One reason is "T cell exhaustion", a term that means T cells that are initially recruited to the tumor to kill it end up losing their effectiveness .The technology covered by this patent application introduces a novel type of T cell which is resistant to the immune suppressive effects of the tumor and prevents this exhaustion. The disclosed technology induces an intracellular program in T cells to endow them with certain features of “younger” cells, thus allowing for enhanced activity against conventional solid tumors such as lung, skin, breast and brain cancers. This includes inhibiting NR2F6, a T cell checkpoint which the Company has been focusing on.David Koos explained:

“CAR-T cells have been in the clinic for 6 years but they have hardly made a dent in treating solid tumors. We hope that through the diligent work of our scientists and collaborators that advancements such as what we announced today will pave the way to bring this incredible cellular immunotherapy to patients suffering from solid tumors such as lung, colon, prostate and others.”

RGBP sits on a pile of patents and has solid fundamentals. This is an OTC stock to keep long term. RGBP’s 10+ patents will bring tremendous value to shareholders, which makes this OTC stock a great pick.https://twitter.com/BuggaTss/status/1556484477005987843


All of the 4 OTC stocks discussed today are good stocks to own. The upside is much greater than the downside at these levels.It’s also very important to eye OTC stocks that have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week to find the best alerts for our subscribers.Remember, all you need is one or two penny stocks to succeed in crushing the market averages.As always, good luck to all (except the shorts)!


Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves, and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is for informational and educational purposes only and does not provide investment advice.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.